Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium

Journal of Clinical Investigation

Volumn 101, Issue 2, 1998, Pages 372-382

  Bitzan, Martin M ^a   Wang, Yang ^a   Lin, Janie ^a   Marsden, Philip A ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Endothelin 1; Endothelin converting enzyme 1; Hemolytic uremic syndrome; MRNA; Nitric oxide synthase

Indexed keywords

ARGININE; CITRULLINE; DACTINOMYCIN; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; GLYCOSIDASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RICIN; VEROTOXIN;

ANIMAL CELL; AORTA; ARTICLE; BLOOD VESSEL WALL; CATTLE; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ESCHERICHIA COLI O157; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM;

EID: 0032518406     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI522     Document Type: Article

References (71)

1. O'Brien, A.D., V.L. Tesh, A. Donohue-Rolfe, M.P. Jackson, S. Olsnes, K. Sandvig, A.A. Lindberg, and G.T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
2. Karmali, M.A., B.T. Steele, M. Petric, and C. Lim. 1983. Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin-producing Escherichia coli. Lancet. 1:619-620.
3. Riley, L.W., R.S. Remis, S.D. Helgerson, H.B. McGee, J.G. Wells, B.R. Davis, R.J. Hebert, E.S. Olcott, L.M. Johnson, N.T. Hargrett, et al. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685.
4. Tarr, P.I. 1995. Escherichia coli O157:H7. Clinical, diagnostic, and epidemiological aspects of human infection. Clin. Infect. Dis. 20:1-10.
5. Linggood, M.A., and J.M. Thompson. 1987. Verotoxin production among porcine strains of Escherichia coli and its association with oedema disease. J. Med. Microbiol. 25:359-362.
6. Habib, R., M. Levy, M.F. Gagnadoux, and M. Broyer. 1982. Prognosis of the hemolytic uremic syndrome in children. Adv. Nephrol. 11:99-128.
7. Richardson, S.E., M.A. Karmali, L.E. Becker, and C.R. Smith. 1988. The histopathology of the hemolytic uremic syndrome associated with Verocytotoxin-producing Escherichia coli infections. Hum. Pathol. 19:1102-1108.
8. Argyle, J.C., R.J. Hogg, T.J. Pysher, P.G. Silva, and R.L. Siegler. 1990. A clinicopathological study of 24 children with hemolytic uremic syndrome. Pediaatr. Nephrol. 4:52-58.
9. O'Brien, J.A., S.K. van Why, M.S. Keller, K.M. Gaudio, T.L. Kennedy, and N.J. Siegel. 1994. Altered renovascular resistance after spontaneous recovery from hemolytic uremic syndrome. Yale J. Biol. Med. 67:1-14.
10. Bergstein, J.M., M. Riley, and N.U. Bang. 1992. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic-uremic syndrome. N. Engl. J. Med. 327:755-759.
11. Benigni, A., and G. Remuzzi. 1994. The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. Prostaglundins Leukot. Essent. Fatty Acids. 51:75-79.
12. Remuzzi, G., and P. Ruggenenti. 1995. The hemolytic uremic syndrome. Kidney Int. 47:2-19.
13. Lingwood, C.A. 1993. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 25:189-211.
14. Sandvig, K., M. Ryd, O. Garred, E. Schweda, P.K. Holm, and B. van Deurs. 1994. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J. Cell Biol. 126:53-64.
15. Lord, J.M., L.M. Roberts, and J.D. Robertus. 1994. Ricin: structure, mode of action, and some current applications. Fed. Am. Soc. Exp. Biol. J. 8: 201-208.
16. Furutani, M., K. Kashiwagi, K. Ito, Y. Endo, and K. Igarashi. 1992. Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin. Arch. Biochem. Biophys. 293:140-146.
17. Wool, I.G., A. Glück, and Y. Endo. 1992. Ribotoxin recognition of ribosomal RNA and a proposal for the mechanism of translation. Trends Biochem. Sci. 17:266-269.
18. Radomski, M.W., R.M.J. Palmer, and S. Moncada. 1987. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1057-1058.
19. Marsden, P.A., and B.M. Brenner. 1991. Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation. Semin. Nephrol. 11:169-185.
20. Flowers, M.A., Y. Wang, R.J. Stewart, B. Patel, and P.A. Marsden. 1995. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am. J. Physiol. 269:H1988-H1997.
21. Petric, M., M.A. Karmali, S. Richardson, and R. Cheung. 1987. Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol. Lett. 41:63-68.
22. Downes, F.P., T.J. Barrett, J.H. Green, C.H. Aloisio, J.S. Spika, N.A. Strockbine, and I.K. Wachsmuth. 1988. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect. Immun. 56:1926-1933.
23. Ramotar, K., B. Boyd, G. Tyrrell, J. Gariepy, C. Lingwood, and J. Brunton. 1990. Characterization of Shiga-like toxin I B subunit purified from over-producing clones of the SLT-I B cistron. Biochem. J. 272:805-811.
24. Richardson, S.E., T.A. Rotman, V. Jay, C.R. Smith, L.E. Becker, M. Petric, N.R. Olivieri, and M.A. Karmali. 1992. Experimental verocytotoxemia in rabbits. Infect. Immun. 60:4154-4167.
25. Marsden, P.A., T.A. Brock, and B.J. Ballermann. 1990. Glomerular endothelial cells respond to calcium-mobilizing agonists with release of EDRF. Am J. Physiol. 258:F1295-F1303.
26. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.
27. Lamas, S., T. Michel, T. Collins, B.M. Brenner, and P.A. Marsden. 1992. Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. J. Clin. Invest. 90:879-887.
28. Lamas, S., P.A. Marsden, G.K. Li, P. Tempst, and T. Michel. 1992. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc. Natl. Acad. Sci. USA. 89:6348-6352.
29. Oberbäumer, I.A. 1992. Retroposons do jump: a B2 element recently integrated in an 18S rDNA gene. Nucl. Acids Res. 20:671-677.
30. Marsden, P.A., D.M. Dorfman, T. Collins, B.M. Brenner, S.H. Orkin, and B.J. Ballermann. 1991. Regulated expression of endothelin 1 in glomerular capillary endothelial cells. Am. J. Physiol. 261:F117-F125.
31. Marsden, P.A., and B.M. Brenner. 1992. Transcriptional regulation of the endothelin-1 gene by TNF-α. Am. J. Physiol. 262:C854-C861.
32. Rubanyi, G.M., and M.A. Polokoff. 1994. Endothelins: molecular biology, biochemistry, pharmocology, physiology, and pathophysiology. Pharmacol. Rev. 46:325-415.
33. Bredt, D.S., and S.H. Snyder. 1989. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. USA. 86:9030-9033.
34. Lamas, S., T. Michel, B.M. Brenner, and P.A. Marsden. 1991. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am. J. Physiol. 261:C634-C641.
35. Leone, A.M., P. Rhodes, V. Fürst, and S. Moncada. 1995. Techniques for the measurement of nitric oxide. Methods Mol. Biol. 41:285-299.
36. Silkoff, P.E., P.A. McClean, A.S. Slutsky, H.U. Furlott, E. Hoffstein, S. Wakita, K.R. Chapman, J.P. Szalai, and N. Zamel. 1997. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am. J. Respir. Crit. Care Med. 155:260-267.
37. Ostroff, S.M., P.I. Tarr, M.A. Neill, J.H. Lewis, N. Hargrett-Bean, and J.M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli 0157:H7 infections. J. lnfect. Dis. 160: 994-998.
38. Bitzan, M., K. Ludwig, M. Klemt, H. Koenig, J. Buren, and D.E. Müller-Wiefel. 1993. The role of Escherichia coli O157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol. Infect. 110:183-196.
39. Biragyn, A., and S.A. Nedospasov. 1995. Lipopolysaccharide-induced expression of TNF-α gene in the macrophage cell line ANA-1 is regulated at the level of transcription processivity. J. Immunol. 155:674-683.
40. Sandvig, K., and B. van Deurs. 1994. Endocytosis and intracellular sorting of ricin and Silica toxin. FEBS Lett. 346:99-102.
41. Shultz, P.J., and L. Raij. 1992. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J. Clin. Invest. 90:1718-1725.
42. Kohan, D.E. 1997. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29:2-26.
43. Siegler, R.L. 1995. The hemolytic uremic syndrome. Pediatr. Clin. N. Am. 42:1505-1529.
44. Sawaf, H., M.J. Sharp, K.J. Youn, P.A. Jewell, and A. Rabbani. 1978. Ischemic colitis and stricture after hemolytic-uremic syndrome. Pediatrics. 61: 315-316.
45. Crisp, D.E., R.L. Siegler, J.F. Bale, and J.A. Thompson. 1981. Hemorrhagic cerebral infarction in the hemolytic-uremic syndrome. J. Pediatr. 99:273-276.
46. Siegler, R.L. 1994. Spectrum of extrarenal involvement in postdiarheal hemolytic-uremic syndrome. J. Pediatr. 125:511-518.
47. Siegler, R.L., S.S. Edwin, R.D. Christofferson, and M.D. Mitchell. 1991. Endothelin in the urine of children with the hemolytic uremic syndrome. Pediatrics. 88:1063-1066.
48. Iwasaki, S., T. Homma, Y. Matsuda, and V. Kon. 1995. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J. Biol. Chem. 270:6997-7003.
49. B receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 50:962-972.
50. Brooks, D.P. 1996. Role of endothelin in renal function and dysfunction. Clin Exp. Pharmacol. Physiol. 23:345-348.
51. Reid, J.L., D. Dawson, and I.M. Macrae. 1995. Endothelin, cerebral ischaemia and infarction. Clin. Exp. Hypertens. 17:399-407.
52. Hof, R., A. Hof, and Y. Takiguchi. 1989. Massive regional differences in the vascular effects of endothelin. J. Hypertens. Suppl. 7:S274-S275.
53. Kurose, I., S. Miura, D. Fukumura, H. Tashiro, H. Imaeda, H. Shiozaki, M. Suematsu, H. Nagata, E. Sekizuka, and M. Tsuchiya. 1992. Role of platelet activating factor on the fibrinolytic activation in the pathogenesis of gastric mucosal damage induced by endothelin-1. Gut. 33:868-871.
54. Kuhn, M., M. Fuchs, F. Beck, S. Martin, J. Jahne, J. Klempnauer, V. Kaever, G. Rechkemmer, and W. Forssmann. 1996. Endothelin-1 potently stimulates chloride secretion and inhibits Na(+)-glucose absorption in human intestine in vitro. J. Physiol. (Lond.). 499:391-402.
55. Inagaki, H., A. Bishop, C. Escrig, J. Wharton, T. Allen-Mersh, and J. Polak. 1991. Localization of endothelinlike immunoreactivity and endothelin binding sites in human colon. Gastroenterology. 101:47-54.
56. Halim, A., N. Kanayama, E. el Maradny, K. Maehara, H. Masahiko, and T. Terao. 1994. Endothelin-1 increased immunoreactive von Willebrand factor in endothelial cells and induced micro thrombosis in rats. Thromb. Res. 76:71-76.
57. Kawana, M., M.E. Lee, E.E. Quertermous, and T. Quertermous. 1995. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol. Cell. Biol. 15:4225-4231.
58. Zubiaga, A.M., J.G. Belasco, and M.E. Greenberg. 1995. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell. Biol. 15:2219-2230.
59. Lagnado, C.A., C.Y. Brown, and G.J. Goodall. 1994. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rieh elements may be UUAUUUA(U/A)(U/ A). Mol. Cell. Biol. 14:7984-7995.
60. Gerez, L., G. Arad, S. Efrat, M. Ketinel, and R. Kaempfer. 1995. Posttranscriptional regulation of human interleukin-2 gene expression at processing of precursor transcripts. J. Biol. Chem. 270:19569-19575.
61. Ross, J. 1995. mRNA stability in mammalian cells. Microbiol. Rev. 59: 423-450.
62. Jacobson, A., and S.W. Peltz. 1996. Interrelationship of the pathways of mRNA decay and translation in eukaryotic cells. Annu. Rev. Biochem. 65:693-739.
63. Tesh, V.L., B. Ramegowda, and J.E. Samuel. 1994. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect. Immun. 62:5085-5094.
64. Ramegowda, B., and V.L. Tesh. 1996. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64:1173-1180.
65. van Setten, P.A., L.A.H. Monnens, R.G.G. Verstraten, L.P.W.J. van den Heuvel, and V.W.M. van Hinsbergh. 1996. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood. 88:174-183.
66. Harel, Y., M. Silva, B. Giroir, A. Weinberg, T.B. Cleary, and B. Beutler. 1993. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J. Clin. Invest. 92:2110-2116.
67. Knight, B. 1979. Ricin - a potent homicidal poison. Br. Med. J. 278:350-351.
68. Farkas-Himsley, H., R. Hill, B. Rosen, S. Arab, and C.A. Lingwood. 1995. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. USA. 92:6996-7000.
69. Simpson, J.C., C. Dascher, L.M. Roberts, J.M. Lord, and W.E. Balch. 1995. Ricin cytotoxicity is sensitive to recycling between the endoplasmic reticulum and the Golgi complex. J. Biol. Chem. 270:20078-20083.
70. Vater, C.A., L.M. Bartle, J.D. Leszyk, J.M. Lambert, and V.S. Goldmacher. 1995. Ricin A chain can be chemically cross-linked to the mammalian ribosomal proteins L9 and L10e. J. Biol. Chem. 270:12933-12940.
71. Iordanov, M.S., D. Pribnow, J.L. Magun, T.H. Dinh, J.A. Pearson, S.L. Y. Chen, and B.E. Magun. 1997. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the α-sarcin/ricin loop in the 28S rRNA. Mol. Cell. Biol. 17:3373-3381.